Previous 10 | Next 10 |
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
The following slide deck was published by Natera, Inc. in conjunction with this Read more ...
SAN CARLOS, Calif. , Jan. 15, 2020 /PRNewswire/ -- Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial in Japan , a prospective, multi-center, randomized trial to investigate ctDNA-guided treatment...
SAN CARLOS, Calif. , Jan. 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today filed suit against CareDx for infringing its U.S. Patent 10,526,658 ("the '658 patent"). The U.S. Patent Office most recently recognize...
SAN CARLOS, Calif. , Jan. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a nationwide multi-center registry study called BESPOKE CRC for patients diagnosed with Stage II-III colorectal cancer (CRC). The study's o...
SAN CARLOS, Calif. , Jan. 8, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Franci...
SAN CARLOS, Calif. , Jan. 6, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of $40 - $50 million in cumulative total contract value (TCV) and has expanded its personalized ctDNA mini...
SAN CARLOS, Calif. , Dec. 19, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination (LCD) to provide insurance coverage for the Prospera donor-derived cell-fr...
Natera Inc. (NASDAQ: NTRA ) with a market cap of $3 billion is a medical diagnostics company focusing on genetic testing across a range of applications. The company is currently commercializing a number of reproduction and prenatal-related DNA tests that are already industry-leading while ex...
SAN CARLOS, Calif. , Nov. 27, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced results of a study published in the Journal of Prenatal Diagnosis which demonstrated that measuring individual fetal frac...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...